# Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

> **NCT01796795** · PHASE2 · SUSPENDED · sponsor: **G&E Herbal Biotechnology Co., LTD** · enrollment: 102 (estimated)

## Conditions studied

- Common Wart

## Interventions

- **DRUG:** Vehicle gel
- **DRUG:** SR-T100 gel with 1.0% of SM
- **DRUG:** SR-T100 gel with 2.3% of SM

## Key facts

- **NCT ID:** NCT01796795
- **Lead sponsor:** G&E Herbal Biotechnology Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2030-09
- **Primary completion:** 2033-04
- **Final completion:** 2033-08
- **Target enrollment:** 102 (ESTIMATED)
- **Why stopped:** Budget issue.
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01796795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01796795, "Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01796795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*